FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308375515> ?p ?o ?g. }

• W4308375515 abstract "<h3>Background</h3> The clinical impact of tumor infiltrating lymphocytes (TIL) cell products is currently limited by suboptimal persistence and potency, as well as the need for high-dose adjuvant IL-2 treatment, which is associated with severe toxicities. Thus, we engineered an IL-2-independent TIL product, based on regulated expression of interleukin 15 (cytoTIL15^TM cells), which has shown anti-tumor efficacy and persistence in human melanoma PDX models. Since the immuno-suppressive tumor microenvironment (TME) hinders cell therapies, we hypothesized that combining pleotropic cytokines of the interferon (IFN), IL-1, or TNF families with IL-15 would further enhance antitumor activity and that our cytoDRiVE® platform would allow pharmacologic control of these potent immune mediators. We tested constitutive and regulated combinations of a representative member of these cytokines with IL-15 in human TIL for <i>in vitro</i> polyfunctionality and <i>in vivo</i> antigen-independent persistence. We also engineered mouse pmel-TCR cells with cytokine combinations for evaluation in the syngeneic B16 melanoma model. <h3>Methods</h3> Human TIL were expanded and engineered with lentiviral vectors to express IL-15 with IFN-alpha, IL-18 (IL-1 family member) or undisclosed TNFSF-X (TNF superfamily member). Expanded TIL were immunophenotyped and assessed for polyfunctionality by flow cytometry after CD3/CD28 stimulation. Engineered TIL were transferred into NSG mice to assess antigen-independent TIL persistence in the absence of exogenous IL-2. Cytokines modified with our carbonic anhydrase 2 (CA2)-based cytoDRiVE® drug responsive domain (DRD) were evaluated for control of protein levels with the CA2 ligand, acetazolamide (ACZ). Cytokine expression was evaluated in flow cytometry and Meso Scale Discovery assays. To assess anti-tumor and TME remodeling capabilities, we used a syngeneic model with transduced pmel-TCR cells adoptively transferred into mice bearing B16 melanomas. <h3>Results</h3> Engineered TIL expressing both IL-15 and either IFN-alpha, IL-18 or TNFSF-X showed similar fold expansion, immunophenotype and polyfunctionality <i>in vitro</i> as TIL expressing only IL-15. Combination cytokine-expressing TIL showed similar <i>in vivo</i> antigen-independent persistence in the absence of IL-2 as TIL engineered with only IL-15. As compared to control pmel cells, sub-optimal cell doses of pmel T cells expressing both IL-15 and either IFN-alpha or, IL-18, showed improved efficacy and TME remodeling, while combining IL-15 with TNFSF-X resulted in significant tumor growth arrest of B16 melanoma tumors without escape. <h3>Conclusions</h3> While IL-15 drives expansion and persistence of cytoTIL15^TM cells without IL-2, adding pleotropic and highly immune-stimulatory members of the IFN, IL-1 or TNF families may provide enhanced efficacy for patients with solid tumors marked by an immunosuppressive TME. <h3>Ethics Approval</h3> All animal studies were IACUC approved" @default.
• W4308375515 created "2022-11-11" @default.
• W4308375515 creator A5003003191 @default.
• W4308375515 creator A5005833293 @default.
• W4308375515 creator A5011404891 @default.
• W4308375515 creator A5017818371 @default.
• W4308375515 creator A5019294072 @default.
• W4308375515 creator A5020688619 @default.
• W4308375515 creator A5026555786 @default.
• W4308375515 creator A5027244202 @default.
• W4308375515 creator A5031974930 @default.
• W4308375515 creator A5041312424 @default.
• W4308375515 creator A5041345886 @default.
• W4308375515 creator A5043406266 @default.
• W4308375515 creator A5049612375 @default.
• W4308375515 creator A5050838416 @default.
• W4308375515 creator A5055963250 @default.
• W4308375515 creator A5061042268 @default.
• W4308375515 creator A5064355632 @default.
• W4308375515 creator A5065160166 @default.
• W4308375515 creator A5073010811 @default.
• W4308375515 creator A5076790826 @default.
• W4308375515 creator A5081690322 @default.
• W4308375515 creator A5086534343 @default.
• W4308375515 creator A5088197754 @default.
• W4308375515 date "2022-11-01" @default.
• W4308375515 modified "2023-09-27" @default.
• W4308375515 title "369 Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with immunosuppressive microenvironments" @default.
• W4308375515 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0369" @default.
• W4308375515 hasPublicationYear "2022" @default.
• W4308375515 type Work @default.
• W4308375515 citedByCount "0" @default.
• W4308375515 crossrefType "proceedings-article" @default.
• W4308375515 hasAuthorship W4308375515A5003003191 @default.
• W4308375515 hasAuthorship W4308375515A5005833293 @default.
• W4308375515 hasAuthorship W4308375515A5011404891 @default.
• W4308375515 hasAuthorship W4308375515A5017818371 @default.
• W4308375515 hasAuthorship W4308375515A5019294072 @default.
• W4308375515 hasAuthorship W4308375515A5020688619 @default.
• W4308375515 hasAuthorship W4308375515A5026555786 @default.
• W4308375515 hasAuthorship W4308375515A5027244202 @default.
• W4308375515 hasAuthorship W4308375515A5031974930 @default.
• W4308375515 hasAuthorship W4308375515A5041312424 @default.
• W4308375515 hasAuthorship W4308375515A5041345886 @default.
• W4308375515 hasAuthorship W4308375515A5043406266 @default.
• W4308375515 hasAuthorship W4308375515A5049612375 @default.
• W4308375515 hasAuthorship W4308375515A5050838416 @default.
• W4308375515 hasAuthorship W4308375515A5055963250 @default.
• W4308375515 hasAuthorship W4308375515A5061042268 @default.
• W4308375515 hasAuthorship W4308375515A5064355632 @default.
• W4308375515 hasAuthorship W4308375515A5065160166 @default.
• W4308375515 hasAuthorship W4308375515A5073010811 @default.
• W4308375515 hasAuthorship W4308375515A5076790826 @default.
• W4308375515 hasAuthorship W4308375515A5081690322 @default.
• W4308375515 hasAuthorship W4308375515A5086534343 @default.
• W4308375515 hasAuthorship W4308375515A5088197754 @default.
• W4308375515 hasBestOaLocation W43083755151 @default.
• W4308375515 hasConcept C147483822 @default.
• W4308375515 hasConcept C17991360 @default.
• W4308375515 hasConcept C19317047 @default.
• W4308375515 hasConcept C203014093 @default.
• W4308375515 hasConcept C2776090121 @default.
• W4308375515 hasConcept C2776107976 @default.
• W4308375515 hasConcept C2777701055 @default.
• W4308375515 hasConcept C2778326572 @default.
• W4308375515 hasConcept C2778690821 @default.
• W4308375515 hasConcept C502942594 @default.
• W4308375515 hasConcept C86803240 @default.
• W4308375515 hasConcept C8891405 @default.
• W4308375515 hasConceptScore W4308375515C147483822 @default.
• W4308375515 hasConceptScore W4308375515C17991360 @default.
• W4308375515 hasConceptScore W4308375515C19317047 @default.
• W4308375515 hasConceptScore W4308375515C203014093 @default.
• W4308375515 hasConceptScore W4308375515C2776090121 @default.
• W4308375515 hasConceptScore W4308375515C2776107976 @default.
• W4308375515 hasConceptScore W4308375515C2777701055 @default.
• W4308375515 hasConceptScore W4308375515C2778326572 @default.
• W4308375515 hasConceptScore W4308375515C2778690821 @default.
• W4308375515 hasConceptScore W4308375515C502942594 @default.
• W4308375515 hasConceptScore W4308375515C86803240 @default.
• W4308375515 hasConceptScore W4308375515C8891405 @default.
• W4308375515 hasLocation W43083755151 @default.
• W4308375515 hasOpenAccess W4308375515 @default.
• W4308375515 hasPrimaryLocation W43083755151 @default.
• W4308375515 hasRelatedWork W2154923100 @default.
• W4308375515 hasRelatedWork W2220102944 @default.
• W4308375515 hasRelatedWork W2322919275 @default.
• W4308375515 hasRelatedWork W2938706471 @default.
• W4308375515 hasRelatedWork W3033156378 @default.
• W4308375515 hasRelatedWork W3039388108 @default.
• W4308375515 hasRelatedWork W3178963881 @default.
• W4308375515 hasRelatedWork W4291378227 @default.
• W4308375515 hasRelatedWork W4308378125 @default.
• W4308375515 hasRelatedWork W4327715451 @default.
• W4308375515 isParatext "false" @default.
• W4308375515 isRetracted "false" @default.
• W4308375515 workType "article" @default.